Highest-materiality recent filing
Director Mike Sayama declines re-election; board shrinks to four, replacement search ongoing
Mike Sayama, independent director, notified SBC he will not stand for re-election at 2026 Annual Meeting.
SBC Medical Q1 revenue falls 9% to $43M; net income drops 47% to $11M
Revenue $43M, -9% YoY; net income $11M, -47% YoY; diluted EPS $0.11, -48% YoY.
CEO sells 3.1M shares in underwritten secondary offering, company receives no proceeds
Selling stockholder CEO Yoshiyuki Aikawa offered 3,100,000 common shares; underwriters have 45-day option for additional 465,000 shares.
SBC Medical Q4 2025 net income up 117% to $14M; EPS $0.14, revenue $40M (-11% YoY)
Net income attributable to SBC Medical Group was $14M, up 117% YoY; EPS $0.14, up 133% YoY.
SBC Medical completes minority investment in U.S. MedSpa chain OrangeTwist, marking U.S. entry
Strategic minority equity investment in OrangeTwist, a U.S. MedSpa chain with 24 locations across 6 states.
SBC Medical announces $20M share repurchase program and effective Form S-3 shelf for up to $50M
Form S-3 shelf registered up to $50M of common or preferred stock, effective Dec 30, 2025; no current offering planned.
SBC Medical gains >50% control of Waqoo via ¥1,900/share tender offer
Tender offer oversubscribed: 637,817 shares tendered vs 575,000 max; SBC to purchase 575,052 shares at ¥1,900 each (total ~¥1,092.5M).
SBC Medical Q3 revenue $43M (-18% YoY) but net income jumps 353% to $13M
Revenue $43M, down 18% YoY; operating income $16M, up 15% YoY.
SBC Medical Group to acquire Waqoo via tender offer; CEO selling 26.6% stake at discounted price
SBCMG to tender for up to 575,000 Waqoo shares at JPY 1,900 each; period Nov 14–Dec 12, 2025.
SBC Medical Q2 2025 revenue $43M (-18% YoY), net income $2.5M (-87% YoY)
Total revenues $43M, down 18% YoY; income from operations $15M, down 47% YoY.
SBC Medical acquires MB career lounge, adding JUN CLINIC to network
Acquired MB career lounge, a Japanese consulting/training firm for medical institutions, for undisclosed cash consideration.
SBC Medical Group added to Russell 3000 Index effective June 30, 2025
Inclusion in the broad-market Russell 3000 Index effective after market open on June 30, 2025.
Shareholders approved declassification of board by ~92.7M votes for, 251 against; all directors' terms end at 2026 annual meeting.
On May 14, 2026, Mike Sayama, an independent director of SBC Medical Group Holdings Incorporated (the “Company”), notified the Company that he would not seek re-election at the Company’s forthcoming 2026 Annual Meeting of Stockholders (the “2026 AGM”).
Max materiality 0.75 · Median 0.65 · Most common event earnings